Insider Buying: ProQR Therapeutics (NASDAQ:PRQR) CEO Purchases $238,500.00 in Stock

Posted by Francis Steltz on Jul 8th, 2026

ProQR Therapeutics N.V. (NASDAQ:PRQR – Get Free Report) CEO Boer Daniel Anton De purchased 150,000 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were bought at an average price of $1.59 per share, for a total transaction of $238,500.00. Following the acquisition, the chief executive officer owned 150,000 shares in the company, valued at $238,500. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

ProQR Therapeutics Stock Performance

Shares of PRQR traded up $0.04 during midday trading on Wednesday, hitting $1.70. The company had a trading volume of 1,118,532 shares, compared to its average volume of 681,486. The company’s 50-day simple moving average is $1.61 and its 200-day simple moving average is $1.68. The firm has a market capitalization of $178.59 million, a P/E ratio of -3.49 and a beta of 0.04. ProQR Therapeutics N.V. has a 1 year low of $1.33 and a 1 year high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) last released its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.15). The firm had revenue of $2.35 million for the quarter, compared to analyst estimates of $5.19 million. ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. Equities analysts predict that ProQR Therapeutics N.V. will post -0.52 earnings per share for the current fiscal year.

Analyst Ratings Changes

PRQR has been the topic of a number of analyst reports. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Oppenheimer started coverage on shares of ProQR Therapeutics in a research note on Thursday, March 12th. They set an “outperform” rating and a $9.00 target price for the company. Chardan Capital dropped their target price on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Wall Street Zen cut ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings cut ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $7.33.

View Our Latest Research Report on ProQR Therapeutics

Institutional Investors Weigh In On ProQR Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of PRQR. Osaic Holdings Inc. grew its holdings in shares of ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares during the last quarter. Guggenheim Capital LLC acquired a new stake in shares of ProQR Therapeutics in the 4th quarter valued at about $35,000. Moody Lynn & Lieberson LLC purchased a new position in ProQR Therapeutics during the 4th quarter worth approximately $50,000. Invesco Ltd. acquired a new position in ProQR Therapeutics during the fourth quarter worth approximately $51,000. Finally, Axiom Investment Management LLC purchased a new stake in ProQR Therapeutics in the first quarter valued at approximately $53,000. 32.65% of the stock is owned by hedge funds and other institutional investors.

About ProQR Therapeutics

(Get Free Report)

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.